Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Operating Leases (2019 - 2025)

Historic Operating Leases for Harvard Bioscience (HBIO) over the last 10 years, with Q3 2025 value amounting to $8.8 million.

  • Harvard Bioscience's Operating Leases rose 1257.5% to $8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.8 million, marking a year-over-year increase of 1257.5%. This contributed to the annual value of $7.5 million for FY2024, which is 2140.1% up from last year.
  • As of Q3 2025, Harvard Bioscience's Operating Leases stood at $8.8 million, which was up 1257.5% from $8.4 million recorded in Q2 2025.
  • In the past 5 years, Harvard Bioscience's Operating Leases ranged from a high of $9.2 million in Q1 2021 and a low of $5.8 million during Q1 2024
  • For the 5-year period, Harvard Bioscience's Operating Leases averaged around $7.7 million, with its median value being $7.8 million (2024).
  • As far as peak fluctuations go, Harvard Bioscience's Operating Leases plummeted by 1859.08% in 2024, and later surged by 5031.28% in 2025.
  • Harvard Bioscience's Operating Leases (Quarter) stood at $8.6 million in 2021, then decreased by 14.06% to $7.4 million in 2022, then dropped by 16.27% to $6.2 million in 2023, then increased by 21.4% to $7.5 million in 2024, then increased by 16.97% to $8.8 million in 2025.
  • Its last three reported values are $8.8 million in Q3 2025, $8.4 million for Q2 2025, and $8.6 million during Q1 2025.